Wie hoch ist der Preis für Shanghai Pharmaceuticals Holding Co., Ltd (601607)

Preis für Shanghai Pharmaceuticals Holding Co., Ltd (601607) ist $2.37

Wie hoch ist die Marktkapitalisierung für Shanghai Pharmaceuticals Holding Co., Ltd (601607)

Marktkapitalisierung für Shanghai Pharmaceuticals Holding Co., Ltd (601607) ist $8.80B

Shanghai Pharmaceuticals Holding Co., Ltd (601607) Gewinne

Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.

Jahr	Gewinn	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Gewinn

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Gewinn	Gewinnunterschied	Land
McKesson Corporation MCK.US	$6.46B	-	US
Cencora, Inc. COR.US	-	-	US
Cardinal Health, Inc. CAH.US	$2.17B	-	US
AmerisourceBergen Corporation ABC.US	-	-	US
Sigma Healthcare Limited SIG.AX	$358.16M	-	AU

Unternehmen

Gewinn

Gewinnunterschied

Land